Cancer Genetics is Pleased to Announce the Appointment of Dr. Paul Rothman, Dean of the Medical Faculty and CEO of Johns Hopk...
February 18 2014 - 7:00AM
Cancer Genetics (Nasdaq:CGIX), an emerging leader in DNA-based
diagnostics, announced today the addition of Paul Rothman, MD, Dean
of the Medical Faculty and CEO of Johns Hopkins Medicine, to the
Company's Board of Directors.
As Dean and CEO, Dr. Rothman oversees both the Johns Hopkins
Health System and the School of Medicine. He joined Johns Hopkins
in July 2012, after having served as the Dean of the Carver College
of Medicine at the University of Iowa and the leader of its
clinical practice plan since 2008. Previously, he served as
head of internal medicine at the University of Iowa, and prior to
that, was vice chairman for research and founding director of the
Division of Pulmonary, Allergy and Critical Care Medicine at
Columbia University College of Physicians and Surgeons, where he
joined the faculty in 1986. He is a Phi Beta Kappa graduate
of the Massachusetts Institute of Technology and earned his medical
degree from Yale University. He trained at
Columbia-Presbyterian Medical Center and accepted a postdoctoral
fellowship at Columbia University prior to joining its school
faculty.
"We are very pleased to have Dr. Rothman join our board of
directors," said Panna Sharma, President and Chief Executive
Officer of Cancer Genetics. "Dr. Rothman's vast experience,
including his ability to lead innovative research in oncology and
his broad knowledge of the US healthcare system will be highly
valuable to our organization. As we strive to develop products that
transform cancer patient management, improve treatment outcomes,
and reduce healthcare costs, his guidance can help provide us
valuable strategic insights."
Dr. Rothman's research has focused on the role cytokines play in
the normal development of blood cells, as well as the abnormal
development of these blood cells as a cause of hematological
cancers, including leukemias. He also studied the role of cytokines
in immune system responses to asthma and allergies. His work has
been consistently funded by the National Institutes of Health.
Dr. Rothman's honors include a James S. McDonnell Foundation
Career Development Award, a Pfizer Scholars Award, a Pew Scholar
Award, a Leukemia Society of America Scholar Award and the
Pharmacia Allergy Research Foundation International Award in 1997.
Dr. Rothman is a member of the American Society for Clinical
Investigation and is a Fellow of the American College of
Physicians. He was elected to the Council of Association of
American Physicians, as a Fellow of the American Association for
the Advancement of Sciences, and as a member of the American
Clinical and Climatological Association.
Cancer Genetics also announced the resignation of Andrew Pecora
from its Board of Directors. "We would like to thank Andrew
for his many years of leadership at Cancer Genetics and his crucial
role in the development of our Company. We wish him well in
his endeavors," said Panna Sharma.
About Cancer Genetics:
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer
diagnostics, servicing some of the most prestigious medical
institutions in the world. Our tests target cancers that are
difficult to diagnose and predict treatment outcomes. These cancers
include hematological, urogenital and HPV-associated cancers. We
also offer a comprehensive range of non-proprietary
oncology-focused tests and laboratory services that provide
critical genomic information to healthcare professionals, as well
as biopharma and biotech companies. Our state-of-the-art reference
lab is focused entirely on maintaining clinical excellence and is
both CLIA certified and CAP accredited and has licensure from
several states including New York State. We have established strong
research collaborations with major cancer centers such as Memorial
Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National
Cancer Institute. For further information, please see
www.cancergenetics.com.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development and potential opportunities for Cancer Genetics, Inc.
products and services, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to,
statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates") should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
maintenance of intellectual property rights and other risks
discussed in the Company's Form 10-Q for the quarter ended
September 30, 2013 and other filings with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date hereof. Cancer Genetics disclaims any obligation to
update these forward-looking statements.
CONTACT: Investor Relations
Michael Rice
Life Science Advisors LLC
646-597-6979
Media Relations
RedChip Companies, Inc.
Paul Kuntz, 800-733-2447, ext. 105
paul@redchip.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2023 to Jul 2024